4 European Projects Found
Searched on 125080 European Projects
FINISHED
A BLUEPRINT of Haematopoietic Epigenomes (BLUEPRINT)
Start date: Oct 1, 2011, End date: Sep 30, 2016,
In response to the call for a high impact initiative on the human epigenome, the BLUEPRINT Consortium has been formed with the aim of generating at least 100 reference epigenomes and studying them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. BLUEPRINT will focus on distinct types of haematopoietic cells from healthy individuals and o ...
Read Project
45
Partners Participants
FINISHED
TreatPolyQ – Industrial Academic Initial Training Network towards treatment of Polyglutamine Diseases (TREATPOLYQ)
Start date: Mar 1, 2011, End date: Feb 28, 2015,
Protein aggregation is a hallmark of many late onset neurodegenerative disorders including Parkinson’s Disease (PD), Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS), prion diseases as well as the group of polyglutamine diseases (polyQ). The aim of this proposal is to create a network of European partners bridging important basic mechanisms involved in proteinopathies, research of mod ...
Read Project
17
Partners Participants
FINISHED
Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington’s Disease by SEN0014196 (PADDINGTON)
Start date: Jul 1, 2010, End date: Dec 31, 2013,
"The Consortium will undertake clinical research activities aimed at ascertaining feasibility of a range of pharmacodynamic readouts for use in the clinical development of SEN0014196 to demonstrate the disease-modifying properties of the compound in Huntington’s Disease. SEN0014196 is a novel and selective SirT1 inhibitor, currently in Phase I clinical development, and enjoys Orphan Status in the ...
Read Project
5
Partners Participants
FINISHED
Initial Training Network on therapeutic approaches and predictive models for neurodegenerative diseases (NEUROMODEL)
Start date: Oct 15, 2008, End date: Oct 14, 2012,
"Neurodegenerative diseases such as Parkinson’s disease (PD) and Huntington’s disease (HD) still lack treatments that are disease modifying. The proposed network is going to address the three most important bottlenecks for finding more effective medicine in brain disorders. Those are: (i) identification and validation of pre-symptomatic and surrogate marker for disease progression, (ii) Develo ...
Read Project
